Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Issue 1 (1st January 2020)

• Record Type: Journal Article
• Authors: Anderson, Danielle E.; Tan, Chee Wah; Chia, Wan Ni; Young, Barnaby E.; Linster, Martin; Low, JennyG. H.; Tan, Yee-Joo; Chen, Mark I.-C.; Smith, Gavin J. D.; Leo, Yee Sin; Lye, David C.; Wang, Lin-Fa
• Is Part Of: Emerging microbes & infections. Volume 9:Issue 1(2020)
• Page Start: 900
• Page End: 902
• Publication Date: 2020-01-01
• Subjects: SARS -- COVID-19 -- antibody -- cross-neutralization -- SARS-CoV-2; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2020.1761267
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.